DK180380A - Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf - Google Patents

Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf

Info

Publication number
DK180380A
DK180380A DK180380A DK180380A DK180380A DK 180380 A DK180380 A DK 180380A DK 180380 A DK180380 A DK 180380A DK 180380 A DK180380 A DK 180380A DK 180380 A DK180380 A DK 180380A
Authority
DK
Denmark
Prior art keywords
cell line
hybrid cell
procedures
producing
monoclonal antibody
Prior art date
Application number
DK180380A
Other languages
English (en)
Other versions
DK154769B (da
DK154769C (da
Inventor
P C S Kung
G Goldstein
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK180380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of DK180380A publication Critical patent/DK180380A/da
Publication of DK154769B publication Critical patent/DK154769B/da
Application granted granted Critical
Publication of DK154769C publication Critical patent/DK154769C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK180380A 1979-04-26 1980-04-25 Monoklonalt antistof, fremstilling heraf, hybridomacellelinie til anvendelse ved fremstilling heraf samt fremgangsmaader til anvendelse heraf DK154769C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3366979 1979-04-26
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same

Publications (3)

Publication Number Publication Date
DK180380A true DK180380A (da) 1980-10-27
DK154769B DK154769B (da) 1988-12-19
DK154769C DK154769C (da) 1989-06-19

Family

ID=21871750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK180380A DK154769C (da) 1979-04-26 1980-04-25 Monoklonalt antistof, fremstilling heraf, hybridomacellelinie til anvendelse ved fremstilling heraf samt fremgangsmaader til anvendelse heraf

Country Status (22)

Country Link
US (1) US4361549A (da)
EP (1) EP0018795B2 (da)
JP (2) JPS55145617A (da)
AT (1) ATE14023T1 (da)
AU (1) AU544791B2 (da)
CA (1) CA1182406A (da)
DE (2) DE18795T1 (da)
DK (1) DK154769C (da)
ES (1) ES490944A0 (da)
FI (1) FI75183C (da)
HK (1) HK23886A (da)
IE (1) IE50422B1 (da)
IL (1) IL59917A (da)
MY (1) MY8600514A (da)
NL (1) NL930131I2 (da)
NO (1) NO159221C (da)
NZ (1) NZ193469A (da)
PH (1) PH16642A (da)
PT (1) PT71147B (da)
SG (1) SG6686G (da)
YU (1) YU48442B (da)
ZA (1) ZA802525B (da)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5158885A (en) * 1987-10-16 1992-10-27 Biomedical Systems Ltd Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
JPH0291833U (da) * 1988-12-29 1990-07-20
JPH0277212U (da) * 1989-01-25 1990-06-13
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
JPH0420550U (da) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JP2000503003A (ja) 1995-12-22 2000-03-14 イムノメディクス，インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
DE69637856D1 (en) 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
CA2310805A1 (en) 1997-11-24 1999-06-03 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US20060142169A1 (en) 2000-11-08 2006-06-29 Bioconcept Laboratories Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
JP5258139B2 (ja) * 2000-11-08 2013-08-07 エフエックスエス・ベンチャーズ・エルエルシー ビタミンｂの形態を含有する改良した眼科用およびコンタクトレンズ用溶液
US7939501B2 (en) * 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
ES2358427T3 (es) * 2003-10-16 2011-05-10 Micromet Ag Elementos de unión a cd-3 desinmunizados multiespecíficos.
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
JP2009500457A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法
EP2037961B1 (en) * 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2008079713A2 (en) * 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
KR20180010347A (ko) 2009-07-17 2018-01-30 바이오아트라, 엘엘씨 생산 숙주에서 항체/단백질 성능과 발현을 동시에 통합 선택하고 진화시키는 방법
JP2013525420A (ja) 2010-04-29 2013-06-20 ナスバックス リミテッド 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物
EP2593797B1 (en) 2010-07-16 2019-05-08 Bioatla, LLC Novel methods of protein evolution
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
AU2011352207B2 (en) 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2015105888A1 (en) 2014-01-07 2015-07-16 Bioatla, Llc Proteins targeting orthologs
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
MX2017006312A (es) 2014-11-17 2017-08-21 Regeneron Pharma Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
TN2017000275A1 (en) 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
DK3411407T3 (da) 2016-02-05 2024-07-01 Orionis Biosciences BV Bispecifikke signaleringsmidler og anvendelser deraf
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3615653A1 (en) 2017-04-27 2020-03-04 Juno Therapeutics GmbH Oligomeric particle reagents and methods of use thereof
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
EP4037774A1 (en) 2019-10-02 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
EP4103204A1 (en) 2020-02-12 2022-12-21 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
US20230087953A1 (en) 2020-02-12 2023-03-23 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
IL296276A (en) 2020-03-10 2022-11-01 Tiziana Life Sciences Plc Antibody preparations for il-6/il-6r and methods of using them
JP2023526278A (ja) 2020-05-13 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
CN115768878A (zh) 2020-06-17 2023-03-07 迪赞纳生命科学公开有限公司 用于增强嵌合抗原受体(car) t细胞疗法的组合物和方法
CN116406274A (zh) 2020-07-30 2023-07-07 迪赞纳生命科学公开有限公司 用于治疗冠状病毒的cd3抗体
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
CA3234994A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (da) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
DE18795T1 (de) 1984-07-19
US4361549A (en) 1982-11-30
AU544791B2 (en) 1985-06-13
EP0018795B2 (en) 1999-04-07
PT71147A (en) 1980-05-01
IL59917A (en) 1983-12-30
NL930131I1 (nl) 1993-11-01
PT71147B (en) 1981-08-11
JPS6362520B2 (da) 1988-12-02
EP0018795A2 (en) 1980-11-12
EP0018795A3 (en) 1981-01-07
NO801214L (no) 1980-10-27
EP0018795B1 (en) 1985-06-26
DK154769B (da) 1988-12-19
AU5775780A (en) 1980-10-30
MY8600514A (en) 1986-12-31
JPH0198478A (ja) 1989-04-17
JPS55145617A (en) 1980-11-13
YU114680A (en) 1984-02-29
NZ193469A (en) 1984-07-06
DK154769C (da) 1989-06-19
NO159221B (no) 1988-08-29
FI75183C (fi) 1988-05-09
FI801342A (fi) 1980-10-27
IE800840L (en) 1980-10-24
DE3070803D1 (en) 1985-08-01
IE50422B1 (en) 1986-04-16
YU48442B (sh) 1998-07-10
JPH0159868B2 (da) 1989-12-20
ATE14023T1 (de) 1985-07-15
CA1182406A (en) 1985-02-12
SG6686G (en) 1986-08-01
FI75183B (fi) 1988-01-29
IL59917A0 (en) 1980-06-30
NL930131I2 (nl) 1998-07-01
ES8105152A1 (es) 1981-05-16
ZA802525B (en) 1981-12-30
PH16642A (en) 1983-12-06
NO159221C (no) 1988-12-07
ES490944A0 (es) 1981-05-16
HK23886A (en) 1986-04-11

Similar Documents

Publication Publication Date Title
DK180380A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
DK517380A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
DK180580A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
DK517480A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
NO159882C (no) Monoklonalt antistoff.
DK517280A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
DK517180A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf

Legal Events

Date Code Title Description
PUP Patent expired